American Neurological Association

16 articles about American Neurological Association

• New Data From Reach2HD Trial Presented At American Neurological Association Annual Meeting

  10/18/2016

• Catabasis To Present The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association’s 2016 Annual Meeting

  10/11/2016

• NeuralStem Inc. Investigator Provides Phase II Update On ALS Cell Therapy At American Neurological Association Annual Meeting

  9/29/2015

• NeuralStem Inc. Investigator To Provide Update On ALS And Alzheimer's At American Neurological Association Annual Meeting

  9/25/2015

• Catalyst Pharmaceutical Partners, Inc. To Present Top-Line Safety And Efficacy Results From Phase 3 Firdapse Trial At 139th Annual Meeting Of The American Neurological Association

  10/8/2014

• AVANIR Pharmaceuticals Announces Data Presentations At The American Neurological Association's (ANA) 2014 Annual Meeting Including Results From The Phase 2 Trial For Treatment Of Agitation In Patients With Alzheimer's Disease

  10/8/2014

• Intra-Cellular Therapies, Inc. To Present Results From Phase 1/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting

  10/7/2014

• Upsher-Smith Laboratories Reports Favorable Results From Phase 1 Clinical Trial of USL255 (Extended-Release Topiramate) at American Neurological Association's 2013 Annual Meeting

  10/15/2013

• Acorda Therapeutics Shows Off Positive Dalfampridine-ER Data in Post-Stroke Deficits at American Neurological Association 2013 Annual Meeting

  10/14/2013

• NeuralStem Inc. Release: Dr. Eva Feldman, Principal Investigator, to Give Update on ALS Trial at American Neurological Association Meeting

  10/10/2013

• International Stem Cell Corporation to Present New Data From Parkinson's Disease Program at the American Neurological Association 2013 Annual Meeting

  9/25/2013

• Alexion Pharmaceuticals Inc. Release: Data From Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients With Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association Annual Meeting

  10/9/2012

• AVANIR Pharmaceuticals Presents Detailed Zenvia Confirmatory Phase III Results in Late-Breaker Session at American Neurological Association Meeting

  10/14/2009

• AVANIR Pharmaceuticals to Present Pivotal Zenvia Phase III Data at American Neurological Association and World Congress on Controversies in Neurology Annual Meetings

  10/6/2009

• AVANIR Pharmaceuticals Presents Data At American Neurological Association Annual Meeting

  9/24/2008

• Researchers Identify Critical Link In Lead-Induced Brain Swelling

  3/22/2004